Clinical Trials Logo

Uterine Cervical Neoplasm clinical trials

View clinical trials related to Uterine Cervical Neoplasm.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05880485 Active, not recruiting - Clinical trials for Uterine Cervical Neoplasm

Online Adaptive Radiotherapy Cervical Cancer With Reduced Margin for Cervical Cancer

Start date: February 2, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Online adaptive radiotherapy (oART) has demonstrated to be feasible to reduce planning target volume (PTV) margins for cervical cancer. To explore the value of reduced margins in oART for cervical cancer, we conducted a prospective clinical trial to determine the clinical efficacy and toxicity of reduced margins.

NCT ID: NCT05869123 Active, not recruiting - Clinical trials for Endometrial Neoplasms

Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer

Start date: October 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Online adaptive radiotherapy (oART) has demonstrated to be feasible to reduce planning target volume (PTV) margins for postoperative treatment of endometrial and cervical cancer. To explore the value of reduced margins in oART for postoperative treatment of endometrial and cervical cancer, we conducted a prospective clinical trial to determine the clinical efficacy and toxicity of reduced margins.

NCT ID: NCT05682950 Active, not recruiting - Clinical trials for Endometrial Neoplasms

Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer

Start date: September 12, 2022
Phase: Phase 2
Study type: Interventional

Online adaptive radiotherapy has demonstrated to be feasible to reduce inter-fractional radiotherapy errors as it re-optimizes treatment plan every fraction. To investigate the extent and value of margin reduction,we conduct a prospective clinical trial to determine the optimal margin and toxicity of smaller margin.

NCT ID: NCT03994055 Active, not recruiting - Cervical Cancer Clinical Trials

Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer

Start date: November 16, 2018
Phase: N/A
Study type: Interventional

During radiation therapy (RT) to pelvic tumors, the small intestine, colon and rectum are inevitably included in the radiation field and are healthy tissues that suffer damage as an adverse effect. Pelvic radiation disease (PRD) is the group of gastrointestinal symptoms experienced by patients that receive pelvic radiation. Intestinal inflammation, tissue damage, oxidative stress and tumor metabolism lead the patient to a catabolic state associated with an increase in energy demands. Also, the painful abdominal symptoms restrict the patients' food intake, leading the patients that develop PRD to an increased risk to develop protein-energy malnutrition and micronutrient deficiencies, all of which affect the patients' quality of life. Studies developed in patients with inflammatory bowel disease have suggested that probiotics may have an anti-inflammatory effect in the intestine. In addition, micronutrients and trace elements provide antioxidant capacity and exert immune-modulating effects during periods of intestinal inflammation. Thus, probiotics and immune-modulating nutrients may provide a means to diminish intestinal inflammation and symptoms associated with PRD. In this project the investigators propose that the nutritional management of cervical cancer patients be based on an anti-inflammatory diet, taking into account the nutritional status, age, comorbidities that the patient may present and symptoms developed during treatment. The nutritional intervention will include food rich in immune-modulating nutrients: omega-3 fatty acids, soluble fiber, antioxidants and polyphenols, and probiotics.